IL139672A - Glucocorticoid receptor antagonists for the tretment of dementia - Google Patents

Glucocorticoid receptor antagonists for the tretment of dementia

Info

Publication number
IL139672A
IL139672A IL13967298A IL13967298A IL139672A IL 139672 A IL139672 A IL 139672A IL 13967298 A IL13967298 A IL 13967298A IL 13967298 A IL13967298 A IL 13967298A IL 139672 A IL139672 A IL 139672A
Authority
IL
Israel
Prior art keywords
dementia
glucocorticoid receptor
receptor antagonist
tretment
receptor antagonists
Prior art date
Application number
IL13967298A
Other languages
English (en)
Other versions
IL139672A0 (en
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IL139672A0 publication Critical patent/IL139672A0/xx
Publication of IL139672A publication Critical patent/IL139672A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
IL13967298A 1998-05-15 1998-10-05 Glucocorticoid receptor antagonists for the tretment of dementia IL139672A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8570398P 1998-05-15 1998-05-15
PCT/US1998/020908 WO1999059596A1 (en) 1998-05-15 1998-10-05 Glucocorticoid receptor antagonists for the treatment of dementia

Publications (2)

Publication Number Publication Date
IL139672A0 IL139672A0 (en) 2002-02-10
IL139672A true IL139672A (en) 2005-11-20

Family

ID=22193399

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13967298A IL139672A (en) 1998-05-15 1998-10-05 Glucocorticoid receptor antagonists for the tretment of dementia

Country Status (12)

Country Link
US (1) US6369046B1 (de)
EP (1) EP1076562B1 (de)
JP (3) JP2003505336A (de)
KR (1) KR20010043630A (de)
CN (1) CN1130200C (de)
AT (1) ATE317699T1 (de)
AU (1) AU756818B2 (de)
CA (1) CA2328411C (de)
DE (1) DE69833502T2 (de)
IL (1) IL139672A (de)
NZ (1) NZ507449A (de)
WO (1) WO1999059596A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
WO2001039664A1 (en) * 1999-12-02 2001-06-07 The General Hospital Corporation Method and apparatus for measuring indices of brain activity
US20010046470A1 (en) * 2000-05-10 2001-11-29 Kieko Morita Diagnoses and treatment of disorders using an alternative glucose pathway
DE60238671D1 (de) * 2001-05-04 2011-02-03 Corcept Therapeutics Inc Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
DK1408981T3 (da) 2001-07-23 2009-01-12 Corcept Therapeutics Inc Fremgangsmåder til forebyggelse af vægtforögelse som fölge af antipsykotiske midler
WO2003020216A1 (en) * 2001-08-31 2003-03-13 Corcept Therapeutics, Inc. Methods for inhibiting cognitive deterioration in adults with down's syndrome
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
JP2005535664A (ja) * 2002-07-02 2005-11-24 コーセプト セラピューティクス, インコーポレイテッド インターフェロン−α治療に関連した精神病を処置するための方法
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
US7473903B2 (en) * 2003-02-12 2009-01-06 General Electric Company Method and apparatus for deposited hermetic cover for digital X-ray panel
EP2201963B1 (de) * 2005-04-05 2016-01-27 Yale University Glutamatmodulationsmittel bei der Behandlung mentaler Störungen
WO2008080083A2 (en) * 2006-12-22 2008-07-03 Washington University High performance imaging system for diffuse optical tomography and associated method of use
US9480425B2 (en) * 2008-04-17 2016-11-01 Washington University Task-less optical mapping of dynamic brain function using resting state functional connectivity
WO2011063453A1 (en) * 2009-11-24 2011-06-03 Commonweath Scientific And Industrial Research Organisation Methods, kits and reagents for diagnosing, aiding diagnosis and/or monitoring progression of a neurological disorder
WO2011150209A1 (en) * 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
WO2015187988A1 (en) * 2014-06-04 2015-12-10 Intellimedix Composition and methods of treating epilepsy and/or epilepsy-related disorders
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
US10261310B2 (en) 2016-06-27 2019-04-16 Amazon Technologies, Inc. Amorphous silicon layer as optical filter for thin film transistor channel
KR20220113767A (ko) 2019-12-11 2022-08-16 코어셉트 쎄라퓨틱스 인코포레이티드 미리코릴란트로 항정신병약-유도 체중 증가를 치료하는 방법
US12194036B2 (en) * 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US5348729A (en) 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
FR2696934B1 (fr) 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
JP2000511404A (ja) 1996-04-09 2000-09-05 ビー・テイー・ジー・インターナシヨナル・リミテツド 神経精神、免疫又は内分泌障害を治療するための7α置換ステロイドの使用

Also Published As

Publication number Publication date
CA2328411A1 (en) 1999-11-25
DE69833502T2 (de) 2006-09-28
CA2328411C (en) 2008-12-16
HK1032535A1 (en) 2001-07-27
US6369046B1 (en) 2002-04-09
IL139672A0 (en) 2002-02-10
EP1076562B1 (de) 2006-02-15
JP2009185067A (ja) 2009-08-20
DE69833502D1 (de) 2006-04-20
CN1130200C (zh) 2003-12-10
KR20010043630A (ko) 2001-05-25
CN1292701A (zh) 2001-04-25
JP2009051864A (ja) 2009-03-12
ATE317699T1 (de) 2006-03-15
AU9683398A (en) 1999-12-06
EP1076562A1 (de) 2001-02-21
NZ507449A (en) 2003-08-29
JP2003505336A (ja) 2003-02-12
WO1999059596A1 (en) 1999-11-25
AU756818B2 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
IL139672A (en) Glucocorticoid receptor antagonists for the tretment of dementia
CY1108562T1 (el) Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
CA2302586A1 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
HK1047050A1 (zh) 治疗轻度智力机能缺陷的方法
NO20003534D0 (no) Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
ES2000299A6 (es) Procedimiento para la preparaciom de nuevos derivados de n-aralquil-piperinmetanol
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
UA87473C2 (en) Muscarinic acetycholine receptor antagonists
IL160649A0 (en) Methods for inhibiting cognitive deterioration in adults with down syndrome
IL164793A0 (en) Methods for increasing the therapeutic response toelectroconvulsive therapy ("ect")
WO2004069202A3 (en) Antiglucocorticoids for the treatment of postpartum psychosis
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
IL158744A0 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
EP1726307A3 (de) Methode zur Behandlung von durch Glycocorticoidstörungen verursachten Psychosen
DE60006948D1 (de) Antagonismus des estrogen-rezeptors-beta und knochenkrankheiten
WO2002020526A3 (en) Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
IL123536A0 (en) 5-HT3 Receptor antagonists for dyskinesia

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees